Evidence map›Paper›PMID 36670100›Full record

ArticleCell death & disease2023

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy.

Pavlina Spiliopoulou, Helena J Janse van Rensburg, Lisa Avery, Vathany Kulasingam, Albiruni Razak, Philippe Bedard, Aaron Hansen, Andrzej Chruscinski, Ben Wang, Maria Kulikova and 7 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03702309 (Liquid Biopsy Evaluation and Repository Development at Princess Margaret), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03702309 recruitingnot on this map

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

TypeobservationalSponsorUniversity Health Network, TorontoRan2017 to 2026Enrolled2,500ConditionsCancer, Breast Cancer, Lung Cancer, Colon Cancer
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Unlocking cancer vaccine potential: What are the key factors?Human vaccines & immunotherapeutics · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Pavlina SpiliopoulouPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-6486-6319
Helena J Janse van RensburgDepartment of Internal Medicine, University of Toronto, Toronto, ON, Canada.
Lisa AveryDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Vathany KulasingamLaboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Albiruni RazakPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Philippe BedardPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Aaron HansenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Andrzej ChruscinskiMutli-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
Ben WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Maria KulikovaLaboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Rachel ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Vanessa SpeersPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Alisa NguyenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jasmine LeePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Bryan CoburnLaboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Anna SpreaficoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Lillian L SiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. lillian.siu@uhn.ca.ORCID 0000-0002-3500-0540
University Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite more than 2 years having elapsed since the onset of SARS-CoV-2 pandemic, a level of hesitation around increased SARS-CoV-2 vaccine toxicity in cancer patients receiving immunotherapy (IO) remains. This hesitation stems from the idea that IO agents could elicit an overwhelming immune stimulation post vaccination and therefore increase the risk of vaccine-related toxicity. The aim of our study was to explore serological responses to SARS-CoV-2 vaccination in patients treated with IO and describe the level of immune stimulation using parameters such as blood cytokines, autoantibody levels and immune related adverse events (irAEs) post vaccination. Fifty-one evaluable patients were enrolled in this longitudinal study. Absolute levels and neutralization potential of anti-SARS-CoV-2 antibodies were not significantly different in the IO group compared to non-IO. Chemotherapy adversely affected seroconversion when compared to IO and/or targeted treatment. Following vaccination, the prevalence of grade ≥2 irAEs in patients treated with IO was not higher than the usual reported IO toxicity. We report, for the first time, that anti-SARS-CoV-2 vaccination, elicited the generation of five autoantibodies. The significantly increased autoantibodies were IgM autoantibodies against beta-2 glycoprotein (p = 0.02), myeloperoxidase (p = 0.03), nucleosome (p = 0.041), SPLUNC2 (p < 0.001) and IgG autoantibody against Myosin Heavy Chain 6 (MYH6) (p < 0.001). Overall, comprehensive analysis of a small cohort showed that co-administration of SARS-CoV-2 vaccine and IO is not associated with increased irAEs. Nevertheless, the detection of autoantibodies post anti-SARS-CoV-2 vaccination warrants further investigation (NCT03702309).

Indexed as

COVID-19NeoplasmsAutoantibodiesCOVID-19 VaccinesHumansImmunotherapyLongitudinal StudiesSARS-CoV-2VaccinationAutoantibodiesCOVID-19 Vaccines

Identifiers

PMID36670100
PMCPMC9853486
OpenAlexW4317679859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.